the comparison of glycemic control between sulfonylureas and repaglinide treated type 2 diabetic patients

the comparison of glycemic control between sulfonylureas and repaglinide treated type 2 diabetic patients - the comparison of efficacy(glycemic control) and safety

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009541

Enrollment

180

Registered

2012-12-13

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetic patients

Interventions

the group A: sulfonylureas the group B:the switch from sulfonylureas to repaglinide.twice-daily taking. the group C:the switch from sulfonylureas to repaglinide.thrice-daily taking.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) taking sulfonylureas (less than half of maximum dose) 2) before registration-HbA1c<8.5% for 3 months or more 3) Age more than 20,less than 85

Exclusion criteria

Exclusion criteria: 1) patients using insulin 2) patients with severe liver dysfunction 3) pregnant women

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026